2026-01-02 - Analysis Report
Okay, here's a comprehensive analysis of Procter & Gamble (PG) based on the data provided.

**1) Return Rate Comparison & Alpha/Beta Analysis**

*   **Company Overview:** Procter & Gamble Co. is a multinational consumer goods corporation.
*   **Return Rate Comparison:**
    *   PG Cumulative Return: 20.02%
    *   VOO (S&P 500) Cumulative Return: 105.07%
    *   Divergence: -85.06
    *   Relative Divergence: 3.8 (meaning it's near the low end of its historical divergence range compared to VOO).

*   **Analysis:** PG has significantly underperformed the S&P 500 over the period examined. The divergence of -85.06 indicates a substantial difference in cumulative returns, and the relative divergence of 3.8 suggests this underperformance is near the lowest point historically.

*   **Alpha, Beta & CAGR Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 13.0% | 66.9% | -17.0% | 0.5 | 215.1 |
| 2017-2019  | 43.0% | 70.1% | 1.0% | 0.5 | 292.3 |
| 2018-2020  | 61.0% | 78.6% | 28.0% | 0.7 | 325.7 |
| 2019-2021  | 70.0% | 78.6% | -6.0% | 0.7 | 382.9 |
| 2020-2022  | 22.0% | 79.3% | 3.0% | 0.6 | 354.7 |
| 2021-2023  | 14.0% | 80.5% | -14.0% | 0.4 | 343.0 |
| 2022-2024  | 4.0% | 80.5% | -26.0% | 0.4 | 392.4 |
| 2023-2025  | 1.0% | 80.3% | -67.0% | 0.2 | 335.4 |

    *   **CAGR (Compound Annual Growth Rate):** The CAGR has significantly decreased in recent periods (2022-2025).
    *   **MDD (Maximum Drawdown):** MDD has been consistently high, hovering around 70-80%, indicating significant volatility.
    *   **Alpha:** Alpha has been negative in recent periods, indicating underperformance relative to the market (or a benchmark). The large negative Alpha in 2023-2025 is particularly concerning.
    *   **Beta:** Beta values are consistently below 1 (closer to 0.5 in most periods and recently 0.2), suggesting PG is less volatile than the overall market. This is typical for a stable, dividend-paying consumer staple company.
    *   **Cap (B) (Market Capitalization):** The Market Cap increased during some years, decreased during others.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** 143.31
*   **Previous Close:** 144.05
*   **Change:** -0.51
*   **5-day SMA:** 144.23
*   **20-day SMA:** 143.60
*   **60-day SMA:** 147.15

*   **Analysis:** The stock is currently trading below its 5-day and 60-day moving averages but around its 20-day moving average. The negative change from the previous close suggests a slight downward trend.

**3) RSI, PPO, MRI, and Expected Return Analysis**

*   **MRI (Market Risk Indicator):** 0.9 (Medium Investment Recommended)
*   **RSI (Relative Strength Index):** 60.52 (Neutral territory, neither overbought nor oversold)
*   **PPO (Percentage Price Oscillator):** 0.13 (Indicates a slight upward trend)
*   **Hybrid Signal:** "cash_0%_Buy 100% of cash" (Indicates a buy signal with no cash allocation.)
*   **Recent Relative Divergence Change:** 1.7 (+) (Short-term increase in relative performance vs. the comparison stock)
*   **Expected Return:** 0.0% (Indicates no expected excess return compared to S&P 500 over a long-term investment horizon.)

*   **Analysis:**
    *   The MRI suggests a medium level of investment risk.
    *   The RSI is neutral.
    *   The positive PPO suggests slight momentum.
    *   Recent relative divergence change indicates that short-term relative performance has increased.
    *   The expected return is 0.0%, suggesting that long-term investment would match the S&P500's return (no excess return).

**4) Recent News & Significant Events**

*   **Key Themes from News Headlines:**
    *   **Analyst Recommendations:** Jim Cramer mentioned PG as a potential stock to consider and has said patience is going to pay off with PG, while Forbes suggests considering PG over Colgate-Palmolive.
    *   **Institutional Selling:** Ninety One North America Inc. sold shares of PG.
    *   **Price Weakness:** Some articles discuss why PG stock hit a 2-year low.
    *   **Investor Considerations:** Articles discuss what investors need to know.

*   **Impact:** The news is mixed. Positive analyst commentary is countered by news of institutional selling and price weakness.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean = 1.92)
*   **Target Price:** Average: $168.95, High: $186.00, Low: $148.00

*   **Analysis:** The analyst consensus is generally positive, with a "Buy" recommendation and a target price significantly higher than the current price.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출        |
|------------|------|-------------|
| 2025-10-24 | 2    | 22.39 B$    |
| 2025-04-24 | 1.58 | 19.78 B$    |
| 2025-01-22 | 1.94 | 21.88 B$    |
| 2024-10-18 | 1.65 | 21.74 B$    |
| 2025-10-24 | 1.65 | 21.74 B$    |

*   **Analysis:**
    *   **EPS (Earnings Per Share):** EPS has fluctuated.
    *   **매출 (Revenue):** Revenue has also fluctuated, with the most recent quarter showing the highest revenue in the table.

**6) Financial Information**

*   **Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $22.39B   | 51.37%        |
| 2025-06-30   | $20.89B   | 49.11%        |
| 2025-03-31   | $19.78B   | 50.98%        |
| 2024-12-31   | $21.88B   | 52.39%        |
| 2024-09-30   | $21.74B   | 52.06%        |

*   **Capital and Profitability:**

| Quarter      | Equity    | ROE   |
|--------------|-----------|-------|
| 2025-09-30   | $53.27B   | 8.92% |
| 2025-06-30   | $52.01B   | 6.95% |
| 2025-03-31   | $52.27B   | 7.21% |
| 2024-12-31   | $51.17B   | 9.05% |
| 2024-09-30   | $51.84B   | 7.64% |

*   **Analysis:**
    *   **Revenue:** Revenue has generally been trending upward.
    *   **Profit Margin:** Profit margins are consistently high, indicating strong profitability.
    *   **Equity:** Equity has shown a general upward trend, although with some fluctuations.
    *   **ROE (Return on Equity):** ROE has fluctuated but remains relatively healthy.

**7) Comprehensive Analysis (Summary)**

*   **Performance:** PG has significantly underperformed the S&P 500 in the period examined. The Alpha also shows underperformance relative to benchmarks in some recent years.
*   **Valuation and Momentum:** The current stock price is slightly below its 5-day and 60-day moving averages. The RSI is neutral and recent divergence change shows that short-term relative performance has increased.
*   **Financial Health:** The company has strong revenue, high profit margins, and a decent ROE.
*   **Analyst Opinion:** Analysts have a generally positive outlook on the stock.
*   **Risk:** The MRI indicates a medium level of investment risk. Maximum Drawdown has been consistently high.
*   **News:** Recent news headlines are mixed, with positive analyst commentary balanced by concerns about institutional selling and price weakness.

**Overall Recommendation:**

The data presents a mixed picture. While PG exhibits financial strength and positive analyst sentiment, its recent underperformance relative to the S&P 500 is concerning. The high Maximum Drawdown indicates a risk of significant price drops. Considering the medium level of investment risk indicated by the MRI, potential investors should carefully weigh the pros and cons before investing in PG. The 0% expected excess return compared to S&P 500 makes PG a candidate only if the investor is looking for low volatility (low Beta), dividend income (not shown, but characteristic of PG), and stability rather than outperformance. The Hybrid Signal indicating a "Buy" suggests the potential for short-term gains, but long-term prospects may be tied to the overall market performance.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.